Doubling the infliximab dose versus halving the infusion intervals in Crohnʼs disease patients with loss of response
Inflammatory Bowel Diseases2012Vol. 18(11), pp. 2026–2033
Citations Over TimeTop 10% of 2012 papers
Lior H. Katz, Javier P. Gisbert, Beth Manoogian, Kirk Lin, Casper Steenholdt, Gerassimos J. Mantzaris, Ashish Atreja, Yulia Ron, Arun Swaminath, Somal Shah, Ailsa Hart, Péter L. Lakatos, Pierre Ellul, Eran Israeli, Mads Naundrup Svendsen, C. Janneke van der Woude, Κωνσταντίνος Κατσάνος, Laura Yun, Epameinondas V. Tsianos, Torben Nathan, María T. Abreu, Iris Dotan, Bret A. Lashner, Jørn Brynskov, Jonathan P. Terdiman, Peter Higgins, María Chaparro, Shomron Ben‐Horin
Abstract
Dose intensification leads to a sustained regained response in 47% of CD patients who lost response to standard infliximab dose, but halving the infusion intervals is probably not superior to dose-doubling. Given the costs and patient inconvenience incurred by an additional infusion visit, the dose-doubling strategy may be preferable to the interval-halving strategy.
Related Papers
- → Impact of Resident Involvement on Orthopaedic Surgery Outcomes: An Analysis of 30,628 Patients from the American College of Surgeons National Surgical Quality Improvement Program Database(2014)112 cited
- → Care fragmentation in hepatopancreatic surgery and postoperative outcomes(2024)15 cited
- → Cardiovascular surgery risk prediction from the patient’s perspective(2011)6 cited
- → Infliximab in children with inflammatory bowel disease in Italy: Safety(2007)
- → Faculty Opinions recommendation of Patient flow variability and unplanned readmissions to an intensive care unit.(2009)